Meibomian Gland Probing for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Massachusetts Eye and Ear Infirmary

No Placebo Group

Trial Summary

What is the purpose of this trial?

The investigators' aim is to study the effects of mechanical expression of meibomian glands on eyelid disease, ocular surface health in the subacute phase of SJS/TEN. The primary outcome is to use meibomian gland imaging to assess the health and caliber of the meibomian glands of both lower eyelids, between the treated and non-treated eyes before and after the intervention. Monitoring of outcomes will be measured by comparing the results of meibography at the initial visit and at the 6-month follow-up. The secondary outcome assessed will be patient symptoms. The Ocular Surface Disease Index survey will be administered before each treatment and patients will be asked to differentiate their symptoms between the two eyes, both before and after the intervention. The investigators hypothesize that mechanical expression of meibomian glands within the first 6 months of SJS/TEN onset will significantly improve ocular surface disease and symptoms in those patients.

Research Team

Eligibility Criteria

Adults over 18 with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) who are in the sub-acute phase (within 6 months of onset) and have meibomitis can participate. Those under 18, past the sub-acute phase, without meibomitis, or with unconfirmed SJS vs. other conditions cannot join.

Inclusion Criteria

I have been diagnosed with Meibomitis.

You have a specific skin condition and received care from certain eye doctors in Massachusetts.

My eye condition started less than 6 months ago.

Exclusion Criteria

I am younger than 18 years old.

My Stevens-Johnson syndrome is no longer in the early stages.

I do not have Meibomitis.

Treatment Details

Interventions

• Meibomian Gland Probing (Other)

Trial Overview The trial is testing if mechanically expressing meibomian glands improves eyelid disease and ocular surface health for patients in the early stages of SJS/TEN. Health will be measured by imaging gland caliber before and after treatment, plus a follow-up at six months.

Who Is Running the Clinical Trial?

Massachusetts Eye and Ear Infirmary

Lead Sponsor

Trials

115

Recruited

15,000+

CarolAnn Williams

Massachusetts Eye and Ear Infirmary

Chief Executive Officer

MBA from Harvard Business School

Aalok Agarwala

Massachusetts Eye and Ear Infirmary

Chief Medical Officer since 2019

MD from University of California, Los Angeles